

**Supplementary Table 1. Platforms, datasets, meta-analysis methods and imputation methods**

<b>Disease/Trait</b>	<b>Genotyping Platform</b>	<b>SNPs passing quality control</b>	<b>Datasets</b>	<b>Meta-analysis methods</b>	<b>SNPs<sup>a</sup></b>	<b>Imputed SNPs<sup>b, c</sup></b>
Bone mineral density- Femoral neck (S19)	Affymetrix, Illumina	~2.5 million	17	F	22	~2.5 M
Bone mineral density- Lumbar spine (S19)	Affymetrix, Illumina	~2.5 million	16	F	27	~2.5 M
Head circumference (infant) (S77)	Affymetrix, Illumina	~2.4 million	7	F	3	~2.4 M
Obesity (childhood) (S9)	Affymetrix, Illumina	~2.7 million	14	F	7	~2.54 M
Brachial circumference (S7)	Affymetrix, Illumina	2,238,430	14	F	0	NR
Adiponectin levels (S12)	Affymetrix, Illumina	NR	18	F; R; Bayesian	10	NR
Creatinine-based estimated GFR (S55)	Affymetrix, Illumina	~2.5 million	26	F	27	~2.5 M
Cystatine-based estimated GFR (S55)	Affymetrix, Illumina	~2.5 million	26	F	3	~2.5 M
Chronic kidney disease (S55)	Affymetrix, Illumina	~2.5 million	25	F	2	~2.5 M
Rheumatoid arthritis (S52)	Affymetrix, Illumina	1,948,139	3	F	7	~2 M
Platelet count (S59)	Affymetrix, Illumina	~2.2 million	7	F	15	~2.2 M
Metabolic syndrome (S40)	Illumina	1,257,079	4	F	1	~0.9 M
Body mass index (S85)	Affymetrix, Illumina	2,474,474	8	F; P-value-based	2	NR
Menopause (age at onset) (S75)	Affymetrix, Illumina	2,551,160	22	F	20	~2.5 M
Atopic dermatitis (S53)	Affymetrix, Illumina	~2.5 million	16	F; R	2	NR
Ankle-brachial index (S48)	Affymetrix, Illumina, Perlegen	~2.5 million	21	F	1	~2.5 M
Multiple sclerosis (S54)	Affymetrix, Illumina	2,529,394	7	F; R	9	~2.5 M
Mean platelet volume (S25)	Affymetrix, Illumina	~2.7 million	13	F	26	NR
Platelet count (S25)	Affymetrix, Illumina	~2.7 million	23	F	39	NR
Aortic stiffness (carotid-femoral pulse wave velocity) (S46)	Affymetrix, Illumina	~2.5 million	9	F	1	~2.5 M
Allergic rhinitis (S60)	Affymetrix, Illumina	2,217,510	6	F	1	~2.2 M
IgE sensitization to grass (S60)	Affymetrix, Illumina	2,217,510	6	F	3	~2.2 M
Alanine aminotransferase (ALT) (S10)	Affymetrix, Illumina, Perlegen	~2.6 million	14	F	4	NR
Alkaline phosphatase (ALP) (S10)	Affymetrix, Illumina, Perlegen	~2.6 million	19	F	14	NR
Gamma glutamyl transpeptidase ( $\gamma$ -GT) (S10)	Affymetrix, Illumina, Perlegen	~2.6 million	21	F	26	NR

Lp-PLA2 mass (S26)	Affymetrix, Illumina	2,661,766	4	F	2	~2.5 M
Lp-PLA2 activity (S26)	Affymetrix, Illumina	2,661,766	3	F	6	~2.5 M
Height (S49)	Affymetrix, Illumina	3,310,998	9	F	2	NR
Type 1 diabetes (S8)	Affymetrix, Illumina	~2.54 million	5	F	19	~2.5 M
Pulmonary function (S70)	Affymetrix, Illumina	~2.5 million	23	F	8	NR
Bipolar disorder (S64)	Affymetrix, Illumina	2,415,422	11	F; R	4	~2.5 M
Common carotid intima media thickness (S5)	Affymetrix, Illumina	~2.5 million	9	F	1	~2.5 M
Internal carotid intima media thickness (S5)	Affymetrix, Illumina	~2.5 million	3	F	0	~2.5 M
Plaque (S5)	Affymetrix, Illumina	~2.5 million	7	F	3	~2.5 M
Diastolic blood pressure (S31)	Affymetrix, Illumina	~2.5 million	29	F	9	NR
Systolic blood pressure (S31)	Affymetrix, Illumina	~2.5 million	29	F	8	NR
Pulse pressure (S82)	Affymetrix, Illumina, Perlegen	NR	35	F	6	~0.5 M
Mean arterial pressure (S82)	Affymetrix, Illumina, Perlegen	NR	35	F	9	~0.5 M
Coffee consumption (S1)	Affymetrix, Illumina, Perlegen	~2.6 million	10	F	1	NR
Type 2 diabetes (S39)	Illumina	568,976	3	F	1	NA
Proinsulin levels (S76)	Affymetrix, Illumina	~2.5 million	4	F	7	~2.5 M
Aging (time to death) (S83)	Affymetrix, Illumina	~2.5 million	9	F	0	~2.5 M
Aging (time to event) (S83)	Affymetrix, Illumina	~2.5 million	9	F	0	~2.5 M
Ankylosing spondylitis (S21)	Illumina	2,223,620	2	F	7	NR
Sudden cardiac arrest (S3)	Affymetrix, Illumina	~2.5 million	5	F	2	~2.5 M
White blood cell count (S61)	Affymetrix, Illumina	2,489,215	7	F	3	~2.2 M
Adiposity (% body fat) (S38)	Affymetrix, Illumina, Perlegen	~2.5 million	15	F	2	NR
Diastolic blood pressure (S35)	Affymetrix, Illumina	~1.7 million	8	F	1	NR
Systolic blood pressure (S35)	Affymetrix, Illumina	~1.7 million	8	F	2	NR
Glioma (S62)	Illumina	424,460	4	F	6	
D-dimer levels (S69)	Affymetrix, Illumina	2,522,393	13	F	3	~2.6 M
Dehydroepiandrosterone sulphate (S88)	Affymetrix, Illumina	~2.5 million	7	F	5	~2.5 M
Caffeine consumption (S11)	Affymetrix, Illumina	~2.5 million	10	F	2	~2.5 M
Alcohol consumption (S65)	Affymetrix, Illumina, Perlegen	~2.5 million	12	F	0	NR

Alzheimer's disease (S28)	Affymetrix, Illumina	496,763	4	F; R	6	0.5 M
Migraine (S42)	Affymetrix, Illumina, Perlegen	~2.5 million	6	F	0	~2.5 M
Coronary heart disease (S66)	Affymetrix, Illumina	~2.3 million	14	F; R	13	~2.3 M
Urinary albumin excretion (S6)	Affymetrix, Illumina	~2.5 million	12	F	0	~2.5 M
C-reactive protein (S14)	Affymetrix, Illumina	~2.5 million	15	F	17	~2.5 M
Ulcerative colitis (S2)	Affymetrix, Illumina	~1.1 million	6	F	33	NR
Parkinson's disease (S32)	Illumina	7,689,524	5	F; R	11	NR
IGF-1 (S34)	Affymetrix, Illumina	~2.5 million	4	F	1	~2.5 M
IGFBP-3 (S34)	Affymetrix, Illumina	~2.5 million	4	F	4	~2.5 M
Personality dimensions (S13)	Affymetrix, Illumina, Perlegen	~2.5 million	10	F	2	~2.5 M
Renal cell carcinoma (S58)	Illumina	586,069	2	F	6	NR
Menarche (age at onset) (S18)	Affymetrix, Illumina	~2.5 million	32	F	42	~2.5 M
Crohn's disease (S22)	Affymetrix, Illumina	953,241	6	F	52	~1 M
QRS duration (S72)	Affymetrix, Illumina	~2.5 million	14	F	25	~2.5 M
Osteoarthritis (knee) (S20)	Affymetrix, Illumina	2,335,627	4	F	0	NR
Retinal venular caliber (S30)	Affymetrix, Illumina	~2.2 million	4	F	5	~2.2 M
Retinal arteriolar caliber (S30)	Affymetrix, Illumina	~2.2 million	4	F	0	~2.2 M
Waist-hip ratio (S27)	Affymetrix, Illumina, Perlegen	2,850,269	32	F; R	12	~2.8 M
Body mass index (S73)	Affymetrix, Illumina, Perlegen	~2.8 million	46	F	19	NR
Urate levels (S86)	Affymetrix, Illumina	~2.5 million	5	F	8	~2.5 M
Gout (S86)	Affymetrix, Illumina	~2.5 million	5	F	2	~2.5 M
Height (S41)	Affymetrix, Illumina, Perlegen	2,834,208	46	F	115	~2.8 M
Asthma (S47)	Illumina	582,892	23	F; R	6	NR
Glycated hemoglobin (S71)	Affymetrix, Illumina	~2.5 million	23	F	10	NR
Calcium levels (S50)	Affymetrix, Illumina	~2.5 million	6	F	1	~2.5 M
Magnesium levels (S45)	Affymetrix, Illumina	~2.5 million	3	F	6	~2.5 M
Sodium (S45)	Affymetrix, Illumina	~2.5 million	3	F	0	~2.5 M
Potassium (S45)	Affymetrix, Illumina	~2.5 million	4	F	0	~2.5 M
Triglycerides (S78)	Affymetrix, Illumina, Perlegen	~2.6 million	46	F	32	NR

HDL cholesterol (S78)	Affymetrix, Illumina, Perlegen	~2.6 million	46	F	47	NR
LDL total (S78)	Affymetrix, Illumina, Perlegen	~2.6 million	46	F	37	NR
Total cholesterol (S78)	Affymetrix, Illumina, Perlegen	~2.6 million	46	F	52	NR
Resting heart rate (RR interval) (S17)	Affymetrix, Illumina	~2.5 million	15	F	9	~2.5 M
Type 2 diabetes (S81)	Affymetrix, Illumina	2,426,886	8	F	10	NR
Phosphorus levels (S36)	Affymetrix, Illumina	~2.5 million	4	F	7	~2.5 M
Vitamin D insufficiency (S84)	Affymetrix, Illumina	2,548,976	5	F	3	NR
Rheumatoid arthritis (S74)	Affymetrix, Illumina	~2,716,259	6	F	6	NR
Heart failure (S68)	Affymetrix, Illumina	2,478,304	4	F	1	~2.5 M
Cigarettes per day (S79)	Affymetrix, Illumina, Perlegen	~2.5 million	13	F; R	1	~2.5 M
Ever vs never smoker (S79)	Affymetrix, Illumina, Perlegen	~2.5 million	16	F; R	0	~2.5 M
Former vs current smokers (S79)	Affymetrix, Illumina, Perlegen	~2.5 million	14	F; R	0	~2.5 M
Age of smoking initiation (S79)	Affymetrix, Illumina, Perlegen	~2.5 million	13	F; R	0	~2.5 M
Birth weight (S23)	Affymetrix, Illumina	~2.4 million	6	F	2	~2.4 M
Intracranial aneurysm (S87)	Illumina	831,534	4	F; Bayesian	6	NR
Urinary bladder cancer (S37)	Illumina	304,703	2	F	0	NA
Coagulation factor VII (S67)	Affymetrix, Illumina	~2.6 million	4	F	5	~2.6 M
Von Willebrand factor (S67)	Affymetrix, Illumina	~2.6 million	5	F	8	~2.6 M
Coagulation factor VIII (S67)	Affymetrix, Illumina	~2.6 million	3	F	5	~2.6 M
Height (S51)	Illumina	420,885	23	F	8	NR
White blood cell count (S33)	Illumina	566,430	10	F	5	NR
Red blood cell count (S33)	Illumina	566,430	10	F	8	NR
Hemoglobin (S33)	Illumina	566,430	10	F	2	NR
Hematocrit (S33)	Illumina	566,430	10	F	2	NR
Mean corpuscular volume (S33)	Illumina	566,430	10	F	15	NR
Mean corpuscular hemoglobin (S33)	Illumina	566,430	10	F	15	NR
Mean corpuscular hemoglobin concentration (S33)	Illumina	566,430	10	F	7	NR
Platelet count (S33)	Illumina	566,430	10	F	6	NR
Gamma glutamyl transpeptidase ( $\gamma$ -GT) (S33)	Illumina	566,430	10	F	2	NR

Aspartate aminotransferase (AST) (S33)	Illumina	566,430	10	F	2	NR
Alanine aminotransferase (ALT) (S33)	Illumina	566,430	10	F	2	NR
Total protein (S33)	Illumina	566,430	10	F	2	NR
Blood urea nitrogen (S33)	Illumina	566,430	10	F	3	NR
Serum creatinine (S33)	Illumina	566,430	10	F	1	NR
Fasting glucose (S16)	Affymetrix, Illumina	~2.5 million	21	F	12	NR
Fasting insulin (S16)	Affymetrix, Illumina	~2.5 million	21	F	0	NR
HOMA-B (S16)	Affymetrix, Illumina	~2.5 million	21	F	3	NR
HOMA-IR (S16)	Affymetrix, Illumina	~2.5 million	21	F	0	NR
Major mood disorders (S44)	Affymetrix, Illumina, Perlegen	~2.1 million	5	F; R	1	~2.1 M
2h glucose challenge (S63)	Affymetrix, Illumina	NR	9	F	3	NR
PR interval (S57)	Affymetrix, Illumina	~2.5 million	8	F	9	~2.5 M
Hemoglobin (S24)	Affymetrix, Illumina	~2.5 million	6	F	7	~2.5 M
Hematocrit (S24)	Affymetrix, Illumina	~2.5 million	6	F	8	~2.5 M
Mean corpuscular volume (S24)	Affymetrix, Illumina	~2.5 million	5	F	16	~2.5 M
Mean corpuscular hemoglobin (S24)	Affymetrix, Illumina	~2.5 million	4	F	9	~2.5 M
Mean corpuscular hemoglobin concentration (S24)	Affymetrix, Illumina	~2.5 million	4	F	2	~2.5 M
Red blood cell count (S24)	Affymetrix, Illumina	~2.5 million	4	F	2	~2.5 M
Atrial fibrillation (S4)	Affymetrix, Illumina	~2.5 million	5	F	2	~2.5 M
Left ventricular mass (S80)	Affymetrix, Illumina	~2.5 million	5	F	3	~2.5 M
Left ventricle internal diastolic dimensions (S80)	Affymetrix, Illumina	~2.5 million	5	F	1	~2.5 M
Left ventricle wall thickness (S80)	Affymetrix, Illumina	~2.5 million	5	F	3	~2.5 M
Left ventricle systolic dysfunction (S80)	Affymetrix, Illumina	~2.5 million	5	F	1	~2.5 M
Adiposity- waist circumference (S43)	Affymetrix, Illumina	2,573,738	16	F	0	~2.5 M
Stroke (S29)	Affymetrix, Illumina	2,194,468	4	F	2	~2.5 M
Fibrinogen (S15)	Affymetrix, Illumina	~2,661,766	6	F	4	~2.5 M
QT interval (S56)	Affymetrix, Illumina	NR	5	F	12	~2.5 M

HOMA-B, homeostatic model assessment beta cell function; HOMA-IR, homeostatic model assessment insulin resistance; Lp-PLA2, lipoprotein-associated phospholipase A2

<sup>a</sup> This column lists the number of SNPs passing the significance threshold used in each GWA meta-analyses.

<sup>b</sup> All studies performed imputations based on HapMap data, except for (S62) that used both HapMap and 1000 Genomes Project data, and (S32) and (S58) that used 1000 Genomes Project data.

<sup>c</sup> All studies performed imputations using some type of hidden Markov model, depending on the specific software used (IMPUTE, MACH, BIMBAM, BEAGLE).

NA, not applicable because no imputation was performed

NR, data not reported

**Supplementary Table 2. Quality control processed for meta-analyses and for constituent studies**

GWA Report	Eligible meta-analyses, N	QC criteria across individual studies	QC criteria used for including SNPs in the meta-analysis				
			MAF	Call rate	HWE	Other	Imputation quality
(S19)	2	Different	≥ 1%	NS	NS	NS	Quality metrics ≥0.3 or 0.4 depending on software
(S77)	1	Different	≥1%	NS	NS	SNPs available in ≥4 datasets	Quality metrics ≥0.3 or 0.4 depending on software
(S9)	1	Common	≥1%	≥95%	10 <sup>-6</sup>	None	Quality metrics ≥0.3 or 0.4 depending on software
(S7)	1	Different	≥1%	NS	NS	NS	Quality metrics ≥0.3 or 0.5 depending on software
(S12)	1	Common	>1%	>95%	10 <sup>-6</sup>	None	Quality metrics ≥0.3 or 0.5 depending on software
(S55)	3	Different	≥1%	NS	NS	NS	NS
(S52)	2	Different	≥1%	NS	NS	NS	Quality metrics ≥0.5
(S59)	1	Different	>1%	>90%	NS	Polymorphic SNPs; SNPs mapped to one genomic location	Quality metrics ≥ 0.5
(S40)	1	Common	≥2%	≥95%	10 <sup>-4</sup>	None	NR
(S85)	1	Different	≥1%	≥90%	10 <sup>-6</sup>	None	Quality metrics ≥0.3 or 0.5 depending on software
(S75)	1	Different	≥1%	NS	NS	NS	Quality score ≥0.2
(S53)	1	Different	≥1%	NS	NS	None	Quality metrics ≥0.4 or 0.5 depending on software
(S48)	1	Different	NS	NS	NS	NS	NR
(S54)	1	Common	>1%	>95%	10 <sup>-6</sup>	None	Quality score ≥0.1
(S25)	2	Different	≥1%	≥90%	10 <sup>-6</sup>	None	Quality metrics ≥0.4
(S46)	1	Different	≥1%	NS	NS	NS	Quality metrics ≥0.3
(S60)	2	Different	NS	NS	NS	NS	Quality metrics ≥0.4
(S10)	3	Different	≥1%	NS	NS	NS	Quality metrics ≥0.3
(S26)	2	Different	≥1%	NS	NS	NS	NR
(S49)	1	Different	≥1%	NS	NS	MAC (sample size × MAF) ≥ 5	Quality metrics ≥0.3
(S8)	1	Common	≥1%	≥95%	10 <sup>-5</sup>	None	Quality metrics ≥0.3
(S70)	1	Different	NS	NS	NS	NS	Quality metrics ≥0.3
(S64)	1	Common	≥1%	≥98%	10 <sup>-6</sup>	Frequency difference to HapMap <0.15; Missing genotype rate between cases	Quality metrics ≥0.3

							and controls per SNP <0.02	
(S5)	3	Different	≥1%	NS	NS	SNPs available in ≥2 datasets	Quality metrics ≥0.3	
(S31)	2	Different	NS	NS	NS	SNPs available in HapMap; SNPs with frequencies similar to HapMap	Quality metrics ≥0.3	
(S82)	2	Different	NS	NS	NS	NS	Quality metrics ≥0.3	
(S1)	1	Different	NS	NS	NS	NS	Quality metrics ≥0.3	
(S39)	1	Common	>1%	>97%	10 <sup>-6</sup>	None	NA	
(S76)	1	Common	>1%	>95%	10 <sup>-6</sup>	None	Quality metrics ≥0.3 or 0.4 depending on software	
(S83)	2	Different	≥1%	NS	NS	NS	Quality metrics ≥0.3	
(S21)	1	Common	≥0.1%	≥98%	5×10 <sup>-20</sup>	Fisher information ≥ 0.975	Quality metrics ≥0.3	
(S3)	1	Different	NS	NS	NS	NS	NR	
(S61)	1	Common	≥1%	≥95%	NR	Polymorphic SNPs; SNPs mapping in one genomic location	Quality metrics ≥0.5	
(S38)	1	Different	NS	NS	NS	NS	Quality metrics ≥0.3 or 0.4 depending on software	
(S35)	1	Different	≥5%	NS	NS	Effective sample size >10,000	Quality metrics ≥0.5	
(S62)	1	Common	>5%	>98%	10 <sup>-5</sup>	None	NR	
(S69)	1	Different	NS	NS	NS	NS	NR	
(S88)	1	Different	≥1%	NS	NS	NS	Quality score ≥0.2	
(S11)	1	Different	≥2%	NS	NS	SNPs available in ≥2 datasets	Quality metrics ≥0.7 or 0.8 depending on software	
(S65)	1	Different	≥1%	NS	NS	NS	Quality metrics ≥0.5	
(S28)	1	NR	NR	NR	NR	NR	NR	
(S42)	1	Different	NS	NS	NS	SNPs available in ≥70% of subjects	NS	
(S66)	1	Different	≥1%	≥98%	10 <sup>-4</sup>	None	Quality metrics ≥0.5	
(S6)	1	Different	>1%	NS	NS	NS	NS	
(S14)	1	Different	NS	NS	NS	NS	NS	
(S2)	1	Different	NS	NS	NS	NS	NS	
(S32)	1	Different	NS	NS	NS	NS	Quality metrics ≥0.3	
(S34)	2	Different	NS	NS	NS	NS	NR	
(S13)	1	Different	≥1%	NS	NS	NS	Quality metrics ≥0.3	
(S58)	1	Common	>5%	>90%	10 <sup>-7</sup>	None	Quality metrics ≥0.3	



(S18)	1	Different	NS	NS	NS	NS	Quality metrics $\geq 0.3$ or 0.4 depending on software
(S22)	1	Different	NR	NR	NR	NR	NR
(S72)	1	Different	NS	NS	NS	NS	NR
(S20)	1	Different	NS	NS	NS	NS	NR
(S30)	2	Different	NS	NS	NS	NS	NR
(S27)	1	Different	NS	NS	NS	MAC (sample size $\times$ MAF) $\geq 3$	Quality metrics $\geq 0.4$
(S73)	1	Different	NS	NS	NS	MAC (sample size $\times$ MAF) $\geq 6$	Quality metrics $\geq 0.3$ or 0.4 depending on software
(S86)	2	Different	$\geq 2\%$	NS	NS	NS	None
(S41)	1	Different	None	NS	NS	MAC (sample size $\times$ MAF) $\geq 3$	Quality metrics $\geq 0.3$ or 0.4 depending on software
(S47)	1	Common	$\geq 1\%$	NS	$10^{-4}$	Genotype missing rate $< 3\%$	NR
(S71)	1	Different	NS	NS	NS	NS	NR
(S50)	1	Different	NS	NS	NS	NS	None
(S45)	3	Different	NS	NS	NS	NS	NS
(S78)	4	Different	$\geq 1\%$	NS	NS	NS	NR
(S17)	1	Different	NS	NS	NS	NS	NR
(S81)	1	Different	NS	NS	NS	NS	NR
(S36)	1	Different	NS	NS	NS	NS	NR
(S84)	1	Different	NS	NS	NS	NS	NR
(S74)	1	Common	$\geq 1\%$	$\geq 95\%$	$10^{-6}$	None	NR
(S68)	1	Different	NS	NS	NS	Post meta-analysis population size-weighted MAF $> 0.015$	NR
(S79)	4	Different	$\geq 1\%$	NS	NS	NS	Quality metrics $\geq 0.7$
(S23)	1	Different	$\geq 1\%$	NS	NS	NS	Quality metrics $\geq 0.3$ or 0.4 depending on software
(S87)	1	Common	$\geq 1\%$	$\geq 95\%$	$10^{-5}$	None	Posterior probability $\geq 0.9$
(S37)	1	Different	NS	NS	NS	$\geq 99.5\%$ consistency between arrays	NA
(S67)	3	Different	NS	NS	NS	NS	NR
(S51)	1	Common	$\geq 1\%$	$\geq 99\%$	$10^{-7}$	Unambiguous clustering of the intensity plots in visual inspection	Quality metrics $> 0.3$
(S33)	14	Common	$\geq 1\%$	$\geq 99\%$	$10^{-7}$	Unambiguous clustering of the intensity plots in visual inspection	Quality metrics $> 0.3$

(S16)	4	Common	≥1%	≥95%	10 <sup>-4</sup> - 10 <sup>-6</sup>	None	Quality metrics ≥0.3 or 0.4 depending on software
(S44)	1	Different	≥5%	NS	NS	NS	Error rate <0.01
(S63)	1	Different	>1%	>95%	10 <sup>-6</sup>	None	Quality metrics ≥0.3 or 0.4 depending on software
(S57)	1	Different	NS	NS	NS	NS	Quality metrics ≥0.3
(S24)	6	Different	≥1%	NS	NS	NS	Observed to expected variance >1.1
(S4)	1	Different	NS	NS	NS	NS	NR
(S80)	4	Different	NS	NS	NS	NS	NR
(S43)	1	Different	≥1%	NS	NS	NS	Quality metrics ≥0.3 or 0.4 depending on software; Imputed genotypes with posterior probability >0.9
(S29)	1	Different	NS	NS	NS	SNPs common in all studies	NR
(S15)	1	Different	NS	NS	NS	NS	NR
(S56)	1	Different	NS	NS	NS	NS	Quality metrics ≥0.3

<sup>a</sup> In this GWA report, all GWA studies applied common quality control steps except for 1 GWA study (WTCCC) which used an older genotyping platform and which applied MAF ≥1%, call rate ≥99% and HWE P>10<sup>-5</sup> as filtering criteria.

QC, quality control; HWE,, Hardy-Weinberg equilibrium, NS, not specified; NR, not reported

**Supplementary Table 3. Genome-wide significance threshold, heterogeneity testing, and replication process**

<b>Disease/Trait</b>	<b>Genome-wide significance</b>	<b>Heterogeneity testing</b>	<b>Replication Process</b>
Bone mineral density- Femoral neck (S19)	$P=5 \times 10^{-08}$	Q, $I^2$	Independent SNPs from discovery stage
Bone mineral density- Lumbar spine (S19)	$P=5 \times 10^{-08}$	Q, $I^2$	Independent SNPs from discovery stage
Head circumference (infant) (S77)	$P=5 \times 10^{-08}$	Q, $I^2$	Strongest SNP per locus or a closely correlated proxy SNP
Obesity (childhood) (S9)	$P=5 \times 10^{-08}$	Q	All new signals reaching a specified significance threshold
Brachial circumference (S7)	$P=5 \times 10^{-08}$	$I^2$	All new signals reaching a specified significance threshold plus biologically plausible SNPs
Adiponectin levels (S12)	$P=5 \times 10^{-07}$ ; BF	Q, $I^2$	NA
Creatinine-based estimated GFR (S55)	$P=5 \times 10^{-08}$	$I^2$	SNPs reaching genome-wide significance plus new SNPs plus SNPs based on “direction test”
Cystatine-based estimated GFR (S55)	$P=5 \times 10^{-08}$	$I^2$	SNPs reaching genome-wide significance plus new SNPs plus SNPs based on “direction test”
Chronic kidney disease (S55)	$P=5 \times 10^{-08}$	$I^2$	SNPs reaching genome-wide significance plus new SNPs plus SNPs based on “direction test”
Rheumatoid arthritis (S52)	$P=5 \times 10^{-08}$	NR	All new signals reaching a specified significance threshold
Platelet count (S59)	$P=5 \times 10^{-08}$	Q, $I^2$	All new signals reaching a specified significance threshold
Metabolic syndrome (S40)	$P=5 \times 10^{-08}$	$I^2$	NA
Body mass index (S85)	$P=5 \times 10^{-08}$	Q	SNP reaching a specified significance threshold for the same trait and previously reported SNPs regardless of significance for a correlated trait
Menopause (age at onset) (S75)	$P=5 \times 10^{-08}$	Q	Independent SNPs from discovery stage
Atopic dermatitis (S53)	$P=5 \times 10^{-08}$	Q	Independent SNPs reaching a predetermined significance threshold
Ankle-brachial index (S48)	$P=5 \times 10^{-08}$	Q	Independent SNPs reaching genome-wide significance plus independent SNPs reaching a lower significance threshold plus SNPs with bioinformatics support.
Multiple sclerosis (S54)	$P=5 \times 10^{-08}$	Q, $I^2$	NA
Mean platelet volume (S25)	$P=5 \times 10^{-08}$	Q	Strongest SNPs per locus
Platelet count (S25)	$P=5 \times 10^{-08}$	Q	Strongest SNPs per locus
Aortic stiffness (carotid-femoral pulse wave velocity) (S46)	$P=5 \times 10^{-08}$	NR	SNPs reaching a predetermined significance threshold
Allergic rhinitis (S60)	$P=5 \times 10^{-08}$	Q	NA
IgE sensitization to grass (S60)	$P=5 \times 10^{-08}$	Q	NA
Alanine aminotransferase (ALT) (S10)	$P=1 \times 10^{-08}$	Q	All independent SNPs reaching a predetermined significance threshold

Alkaline phosphatase (ALP) (S10)	$P=1 \times 10^{-08}$	Q	All independent SNPs reaching a predetermined significance threshold
Gamma glutamyl transpeptidase ( $\gamma$ -GT) (S10)	$P=1 \times 10^{-08}$	Q	All independent SNPs reaching a predetermined significance threshold
Lp-PLA2 mass (S26)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Lp-PLA2 activity (S26)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Height (S49)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	SNP reaching a specified significance threshold
Type 1 diabetes (S8)	$P=5 \times 10^{-08}$	Q	Independent SNPs reaching a predetermined significance threshold and with no evidence of heterogeneity from previously unreported loci.
Pulmonary function (S70)	$P=5 \times 10^{-08}$	Q	All new signals reaching a specified significance threshold
Bipolar disorder (S64)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	SNP reaching a specified significance threshold
Common cIMT (S5)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	SNP reaching a specified significance threshold
Internal cIMT (S5)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	No SNPs eligible for replication
Plaque (S5)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	SNPs reaching a specified significance threshold
Diastolic blood pressure (S31)	$P=5 \times 10^{-08}$	NR	Independent SNPs reaching a specified significance threshold
Systolic blood pressure (S31)	$P=5 \times 10^{-08}$	NR	Independent SNPs reaching a specified significance threshold
Pulse pressure (S82)	$P=5 \times 10^{-08}$	NR	SNPs reaching a specified significance threshold for a correlated trait
Mean arterial pressure (S82)	$P=5 \times 10^{-08}$	NR	SNPs reaching a specified significance threshold for a correlated trait
Coffee consumption (S1)	$P=5 \times 10^{-08}$	Q	SNPs reaching a specified significance threshold
Type 2 diabetes (S39)	$P=5 \times 10^{-08}$	Q	SNPs reaching a specified significance threshold
Proinsulin levels (S76)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	Independent SNPs reaching a predetermined significance threshold plus biologically plausible SNPs
Aging (time to death) (S83)	$P=5 \times 10^{-08}$	NR	A subset of the strongest SNPs from discovery stage
Aging (time to event) (S83)	$P=5 \times 10^{-08}$	NR	No SNPs eligible for replication
Ankylosing spondylitis (S21)	$P=5 \times 10^{-08}$	Q	Criteria not specified
Sudden cardiac arrest (S3)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	Independent SNPs reaching a predetermined significance threshold
White blood cell count (S61)	$P=2.5 \times 10^{-08}$	Q, I <sup>2</sup>	Newly identified SNPs
Adiposity (% body fat) (S38)	$P=5 \times 10^{-08}$	I <sup>2</sup>	SNPs reaching a predetermined significance threshold
Diastolic blood pressure (S35)	$P=5 \times 10^{-08}$	Q	Independent SNPs reaching a predetermined significance threshold plus independent SNPs reaching a lower threshold but with consistent association signals across the individual datasets
Systolic blood pressure (S35)	$P=5 \times 10^{-08}$	Q	Independent SNPs reaching a predetermined significance threshold plus independent SNPs reaching a lower threshold but with consistent association signals across the individual datasets

Glioma (S62)	$P=5 \times 10^{-07}$	Q, I <sup>2</sup>	NA
D-dimer levels (S69)	$P=5 \times 10^{-08}$	NR	NA
Dehydroepiandrosterone sulphate (S88)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Caffeine consumption (S11)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	NA
Alcohol consumption (S65)	$P=5 \times 10^{-08}$	NR	SNPs reaching a predetermined significance threshold plus biologically plausible SNPs
Alzheimer's disease (S28)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	SNPs reaching a predetermined significance threshold
Migraine (S42)	$P=5 \times 10^{-08}$	NR	A subset of SNPs reaching a predetermined significance threshold and selected to be maximally informative given the LD between them
Coronary heart disease (S66)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	New SNPs reaching a predetermined significance threshold
Urinary albumin excretion (S6)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	Strongest independent SNPs reaching a predetermined significance and MAF threshold
C-reactive protein (S14)	$P=5 \times 10^{-08}$	Q	SNPs reaching genome-wide significance plus SNPs a lower significance threshold
Ulcerative colitis (S2)	$P=5 \times 10^{-08}$	NR	SNPs reaching a predetermined significance threshold and not previously replicated
Parkinson's disease (S32)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	SNPs reaching genome-wide significance and quality control in a custom array
IGF-1 (S34)	$P=5 \times 10^{-08}$	NR	NA
IGFBP-3 (S34)	$P=5 \times 10^{-08}$	NR	NA
Personality dimensions (S13)	$P=5 \times 10^{-08}$	Q	Replication of the SNPs that turned out genome-wide significant was performed in five independent samples
Renal cell carcinoma (S58)	$P=5 \times 10^{-07}$	Q	Independent SNPs reaching genome-wide significance
Menarche (age at onset) (S18)	$P=5 \times 10^{-08}$	Q	All newly identified independent SNPs reaching a predetermined significance threshold
Crohn's disease (S22)	$P=5 \times 10^{-08}$	Breslow-Day	SNPs reaching a specified significance threshold
QRS duration (S72)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	SNPs reaching genome-wide significance in the discovery stage and SNPs reaching a specified significance threshold
Osteoarthritis (knee) (S20)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	SNPs reaching a predetermined significance threshold
Retinal venular caliber (S30)	$P=5 \times 10^{-08}$	NR	Independent genome-wide significant SNPs
Retinal arteriolar caliber (S30)	$P=5 \times 10^{-08}$	NR	Independent genome-wide significant SNPs
Waist-hip ratio (S27)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	Independent SNPs reaching a specified significance threshold
Body mass index (S73)	$P=5 \times 10^{-08}$	Q	Independent SNPs reaching genome-wide significance or a predetermined significance threshold
Urate levels (S86)	$P=5 \times 10^{-08}$	NR	NA
Gout (S86)	$P=5 \times 10^{-08}$	NR	NA
Height (S41)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	All new signals reaching a specified significance threshold

Asthma (S47)	$P=7.2 \times 10^{-08}$	Q, $I^2$	NA
Glycated hemoglobin (S71)	$P=5 \times 10^{-08}$	Q, $I^2$	SNPs previously selected by interim analysis
Calcium levels (S50)	$P=5 \times 10^{-08}$	NR	NA
Magnesium levels (S45)	$P=5 \times 10^{-08}$	Q	SNPs reaching genome-wide significance plus SNPs reaching a predetermined significance threshold
Sodium (S45)	$P=5 \times 10^{-08}$	Q	SNPs reaching genome-wide significance plus SNPs reaching a predetermined significance threshold
Potassium (S45)	$P=5 \times 10^{-08}$	Q	SNPs reaching genome-wide significance plus SNPs reaching a predetermined significance threshold
Triglycerides (S78)	$P=5 \times 10^{-08}$	Q	Lead SNPs were tested in European and non-European samples
HDL cholesterol (S78)	$P=5 \times 10^{-08}$	Q	Lead SNPs were tested in European and non-European samples
LDL cholesterol (S78)	$P=5 \times 10^{-08}$	Q	Lead SNPs were tested in European and non-European samples
Total cholesterol (S78)	$P=5 \times 10^{-08}$	Q	Lead SNPs were tested in European and non-European samples
Resting heart rate (RR interval) (S17)	$P=5 \times 10^{-08}$	NR	NA
Type 2 diabetes (S81)	$P=5 \times 10^{-08}$	Q, $I^2$	All SNPs reaching a specified significance threshold
Phosphorus levels (S36)	$P=4 \times 10^{-07}$	NR	Top signals
Vitamin D insufficiency (S84)	$P=5 \times 10^{-08}$	NR	SNPs reaching a specified significance threshold
Rheumatoid arthritis (S74)	$P=5 \times 10^{-08}$	Q	SNPs reaching a specified significance threshold plus previously reported SNPs associated with correlated traits plus biologically/functionally plausible SNPs
Heart failure (S68)	$P=5 \times 10^{-07}$	NR	NA
Cigarettes per day (S79)	$P=5 \times 10^{-08}$	$I^2$	A subset of the most significant SNPs
Ever vs. never smoker (S79)	$P=5 \times 10^{-08}$	$I^2$	A subset of the most significant SNPs
Former vs. current smokers (S79)	$P=5 \times 10^{-08}$	$I^2$	A subset of the most significant SNPs
Age of smoking initiation (S79)	$P=5 \times 10^{-08}$	$I^2$	No SNPs eligible for replication
Birth weight (S23)	$P=5 \times 10^{-08}$	Q, $I^2$	Strongest SNP per locus or a closely correlated proxy SNP
Intracranial aneurysm (S87)	$P=5 \times 10^{-08}$ ; PPA, BF	Q, $I^2$ , $\tau^2$	The genotyped SNP with the highest PPA plus two additional SNPs per locus for each independent signal
Urinary bladder cancer (S37)	$P=1.6 \times 10^{-07}$	Q, $I^2$	Not previously replicated SNPs
Coagulation factor VII (S67)	$P=5 \times 10^{-08}$	Q	All new signals reaching genome-wide significance
Von Willebrand factor (S67)	$P=5 \times 10^{-08}$	Q	All new signals reaching genome-wide significance
Coagulation factor VIII (S67)	$P=5 \times 10^{-08}$	Q	No SNPs eligible for replication

Height (S51)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	NA
White blood cell count (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Red blood cell count (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Hemoglobin (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Hematocrit (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Mean corpuscular volume (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Mean corpuscular hemoglobin (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Mean corpuscular hemoglobin concentration (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Platelet count (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Gamma glutamyl transpeptidase ( $\gamma$ -GT) (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Aspartate aminotransferase (AST) (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Alanine aminotransferase (ALT) (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Total protein (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Blood urea nitrogen (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Serum creatinine (S33)	$P=5 \times 10^{-08}$	I <sup>2</sup>	NA
Fasting glucose (S16)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	All independent SNPs reaching a specified significance threshold plus biologically plausible SNPs
Fasting insulin (S16)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	All independent SNPs reaching a specified significance threshold plus biologically plausible SNPs
HOMA-B (S16)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	All independent SNPs reaching a specified significance threshold plus biologically plausible SNPs
HOMA-IR (S16)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	All independent SNPs reaching a specified significance threshold plus biologically plausible SNPs
Major mood disorders (S44)	$P=7.2 \times 10^{-08}$	Q, I <sup>2</sup>	No details on which SNPs were followed-up
2h glucose challenge (S63)	$P=5 \times 10^{-08}$	Q	Independent SNPs reaching a specified significance threshold and SNPs with biological plausibility
PR interval (S57)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	NA
Hemoglobin (S24)	$P=5 \times 10^{-08}$	NR	SNPs reaching genome-wide significance in the discovery meta-analysis
Hematocrit (S24)	$P=5 \times 10^{-08}$	NR	SNPs reaching genome-wide significance in the discovery meta-analysis
Mean corpuscular volume (S24)	$P=5 \times 10^{-08}$	NR	SNPs reaching genome-wide significance in the discovery meta-analysis
Mean corpuscular hemoglobin (S24)	$P=5 \times 10^{-08}$	NR	SNPs reaching genome-wide significance in the discovery meta-analysis
Mean corpuscular hemoglobin	$P=5 \times 10^{-08}$	NR	SNPs reaching genome-wide significance in the discovery meta-analysis

---

concentration (S24)			
Red blood cell count (S24)	$P=5 \times 10^{-08}$	NR	SNPs reaching genome-wide significance in the discovery meta-analysis
Atrial fibrillation (S4)	$P=5 \times 10^{-08}$	Q	SNPs reaching a predetermined significance threshold and available at a minimum number of datasets
Left ventricular mass (S80)	$P=5 \times 10^{-07}$	NR	Strongest SNP per locus reaching genome-wide significance
Left ventricle internal diastolic dimensions (S80)	$P=5 \times 10^{-07}$	NR	Strongest SNP per locus reaching genome-wide significance
Left ventricle wall thickness (S80)	$P=5 \times 10^{-07}$	NR	Strongest SNP per locus reaching genome-wide significance
Left ventricle systolic dysfunction (S80)	$P=5 \times 10^{-07}$	NR	Strongest SNP per locus reaching genome-wide significance
Adiposity- waist circumference (S43)	$P=5 \times 10^{-08}$	Q, I <sup>2</sup>	Independent SNPs reaching a predetermined significance threshold for the same or a correlated trait plus biologically plausible SNPs
Stroke (S29)	$P=5 \times 10^{-08}$	NR	Independent SNPs reaching genome-wide significance
Fibrinogen (S15)	$P=5 \times 10^{-08}$	NR	Independent SNPs reaching genome-wide significance
QT interval (S56)	$P=5 \times 10^{-08}$	NR	Strongest SNP per locus reaching a predetermined significance threshold

---

BF, Bayes factor; HOMA-B, homeostatic model assessment beta cell function; HOMA-IR, homeostatic model assessment insulin resistance; Lp-PLA2, lipoprotein-associated phospholipase A2; PPA, posterior probability of association; SNP, single nucleotide polymorphism

NR, not reported

Q: Cochran's Q-statistic



**Supplementary Table 4. Diversity in ancestry and phenotypes and cross-phenotype checks**

<b>Disease/Trait</b>	<b>Diverse ancestries</b>	<b>Diverse phenotypes</b>	<b>Phenotype cross-checks</b>
Bone mineral density- Femoral neck (S19)	Yes	No	Fractures
Bone mineral density- Lumbar spine (S19)	Yes	No	Fractures
Head circumference (infant) (S77)	No	No	Intracranial volume in adulthood; trimester fetal head circumference and head circumference at birth; height
Obesity (childhood) (S9)	No	No	BMI
Brachial circumference (S7)	No	No	BMI, WHR, weight, T2D, fasting glucose, fasting insulin, HbA1c, 2h glucose test
Adiponectin levels (S12)	Yes	No	Type 2 diabetes; total cholesterol; LDL; HDL; triglycerides; waist to hip ratio
Creatinine-based estimated GFR (S55)	Yes	No	Urinary albumin-to-creatinine ratio; microalbuminuria; BP; MI
Cystatine-based estimated GFR (S55)	No	No	Urinary albumin-to-creatinine ratio; microalbuminuria; BP; MI
Chronic kidney disease (S55)	Yes	No	Urinary albumin-to-creatinine ratio; microalbuminuria; BP; MI
Rheumatoid arthritis (S52)	Yes	No	Systemic lupus erythematosus; Grave's disease
Platelet count (S59)	Yes	No	Platelet aggregation
Metabolic syndrome (S40)	No	MetS component traits	Serum metabolites
Body mass index (S85)	No	No	No
Menopause (age at onset) (S75)	No	No	No
Atopic dermatitis (S53)	No	No	Asthma; total serum IgE levels
Ankle-brachial index (S48)	No	PAD	CAD; MI
Multiple sclerosis (S54)	NR	No	Crohn's disease, ulcerative colitis, celiac disease, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, psoriasis
Mean platelet volume (S25)	Yes	No	Hb, MCV, RBC
Platelet count (S25)	Yes	No	Hb, MCV, RBC
Aortic stiffness (carotid-femoral pulse wave velocity) (S46)	No	No	CAD, heart failure, pulse rate, chronic kidney disease, GFR
Allergic rhinitis (S60)	No	No	Birth order
IgE sensitization to grass (S60)	No	No	Birth order

Alanine aminotransferase (ALT) (S10)	Yes	No	Hepatic steatosis
Alkaline phosphatase (ALP) (S10)	Yes	No	Hepatic steatosis
Gamma glutamyl transpeptidase ( $\gamma$ -GT) (S10)	Yes	No	Hepatic steatosis
Lp-PLA2 mass (S26)	No	No	CAD/CHD
Lp-PLA2 activity (S26)	No	No	CAD/CHD
Height (S49)	Yes	No	No
Type 1 diabetes (S8)	No	No	No
Pulmonary function (S70)	No	FEV1, FEV1/FVC	Smoking amount; ever smoking versus never smoking; height; lung cancer
Bipolar disorder (S64)	No	No	Schizophrenia
Common cIMT (S5)	No	Internal cIMT; plaque	CAD
Internal cIMT (S5)	No	No	No
Plaque (S5)	No	Common cIMT; internal cIMT	Coronary artery disease
Diastolic blood pressure (S31)	Yes	Hypertension	Levels of circulating serum metabolites, left ventricular mass, left ventricular wall thickness, incident heart failure, incident and prevalent stroke, prevalent CAD, kidney disease and measures of kidney function
Systolic blood pressure (S31)	Yes	Hypertension	Levels of circulating serum metabolites, left ventricular mass, left ventricular wall thickness, incident heart failure, incident and prevalent stroke, prevalent CAD, kidney disease and measures of kidney function
Pulse pressure (S82)	No	No	SBP, DPB
Mean arterial pressure (S82)	No	No	No
Coffee consumption (S1)	No	No	No
Type 2 diabetes (S39)	Yes	No	No
Proinsulin levels (S76)	No	32,33-split proinsulin; insulinogenic index; C-peptide	Fasting and 2h glucose and insulin, HOMA-B, HOMA-IR, HbA1c, type 2 diabetes, BMI, CAD
Aging (time to death) (S83)	No	Aging (time to event)	No
Aging (time to event) (S83)	NR	Aging (time to death)	No
Ankylosing spondylitis (S21)	No	No	No
Sudden cardiac arrest (S3)	No	No	QRS interval, QT interval, RR interval
White blood cell count (S61)	Yes	WBC subtypes	No

Adiposity (% body fat) (S38)	Yes	No	Lipid profiles, indices of insulin sensitivity, fat distribution, leptin, adiponectin
Diastolic blood pressure (S35)	No	Hypertension	BMI, fasting plasma glucose and lipids, CAD
Systolic blood pressure (S35)	No	Hypertension	BMI, fasting plasma glucose and lipids, CAD
Glioma (S62)	No	No	No
D-dimer levels (S69)	NR	No	No
Dehydroepiandrosterone sulphate (S88)	No	No	No
Caffeine consumption (S11)	No	No	No
Alcohol consumption (S65)	No	No	No
Alzheimer's disease (S28)	No	Alzheimer's disease age at onset	No
Migraine (S42)	No	No	No
Coronary heart disease (S66)	No	No	LDL, HDL, total cholesterol, HTN, BMI, type 2 diabetes, smoking
Urinary albumin excretion (S6)	Yes	Microalbuminuria, urinary albumin to creatinine ratio	Time to persistent microalbuminuria
C-reactive protein (S14)	No	No	MI, CHD
Ulcerative colitis (S2)	No	No	Crohn's disease
Parkinson's disease (S32)	No	No	No
IGF-1 (S34)	NR	No	No
IGFBP-3 (S34)	NR	No	No
Personality dimensions (S13)	No	Types of personality dimension	No
Renal cell carcinoma (S58)	No	No	No
Menarche (age at onset) (S18)	No	No	BMI, WHR, obesity, height
Crohn's disease (S22)	No	No	No
QRS duration (S72)	No	No	Conduction defect, PR interval, QT interval
Osteoarthritis (knee) (S20)	Yes	No	No
Retinal venular caliber (S30)	No	No	Central retinal venular equivalent; CAD; stroke; MI, HTN, type 2 diabetes
Retinal arteriolar caliber (S30)	No	No	Central retinal venular equivalent; CAD; stroke; MI, HTN, type 2 diabetes

Waist-hip ratio (S27)	No	No	BMI, WC, hip circumference, TGs, LDL, HDL, fasting glucose, fasting insulin, HOMA-IR, 2h glucose, T2D
Body mass index (S73)	No	Overweighth; obsese	Weight, body fat percentage, type 2 diabetes, 2h glucose, fasting glucose, fasting insulin, HOMA-B, HOMA-IR, HDL, LDL, TGs, height
Urate levels (S86)	No	No	SBP, DBP, glucose, Insulin, GFR, CKD, CHD
Gout (S86)	No	No	SBP, DBP, glucose, Insulin, GFR, CKD, CHD
Height (S41)	No	No	No
Asthma (S47)	No	No	Serum IgE
Glycated hemoglobin (S71)	No	No	Type 2 diabetes, CAD, fasting glucose, 2h glucose, fasting insulin, HOMA-IR, HOMA-B, 2h-insulin, BMI, Hb, MCH, MCV, transferin, iron
Calcium levels (S50)	No	No	Serum magnesium, phosphorus, PTH; LS-BMD, FN-BMD; kidney stone disease
Magnesium levels (S45)	No	No	GFR, SBP, DBP, fasting glucose, BMD
Sodium (S45)	No	No	GFR, SBP, DBP, fasting glucose, BMD
Potassium (S45)	No	No	GFR, SBP, DBP, fasting glucose, BMD
Triglycerides (S78)	Yes	No	CAD, hyperlipidemia, extreme lipid levels
HDL cholesterol (S78)	Yes	No	CAD, hyperlipidemia, extreme lipid levels
LDL cholesterol (S78)	Yes	No	CAD, hyperlipidemia, extreme lipid levels
Total cholesterol (S78)	Yes	No	CAD, hyperlipidemia, extreme lipid levels
Resting heart rate (RR interval) (S17)	No	No	No
Type 2 diabetes (S81)	No	No	Fasting glucose, fasting insulin, HOMA-B, HOMA-IR, BMI
Phosphorus levels (S36)	No	No	No
Vitamin D insufficiency (S84)	No	No	Clinical vitamin D insufficiency; serum concentrations of vitamin D binding protein
Rheumatoid arthritis (S74)	No	No	No
Heart failure (S68)	No	No	No
Cigarettes per day (S79)	No	No	No
Ever vs never smoker (S79)	No	No	No
Former vs current smokers (S79)	No	No	No
Age of smoking initiation (S79)	No	No	No

Birth weight (S23)	Yes	No	Birth length, birth head circumference, ponderal index, T2D, FPG
Intracranial aneurysm (S87)	Yes	No	No
Urinary bladder cancer (S37)	No	No	Recurrence-free survival; smoking behavior
Coagulation factor VII (S67)	No	No	No
Von Willebrand factor (S67)	No	No	No
Coagulation factor VIII (S67)	No	No	No
Height (S51)	No	No	No
White blood cell count (S33)	No	No	No
Red blood cell count (S33)	No	No	No
Hemoglobin (S33)	No	No	No
Hematocrit (S33)	No	No	No
Mean corpuscular volume (S33)	No	No	No
Mean corpuscular hemoglobin (S33)	No	No	No
Mean corpuscular hemoglobin concentration (S33)	No	No	No
Platelet count (S33)	No	No	No
Gamma glutamyl transpeptidase ( $\gamma$ -GT) (S33)	No	No	No
Aspartate aminotransferase (AST) (S33)	No	No	No
Alanine aminotransferase (ALT) (S33)	No	No	No
Total protein (S33)	No	No	No
Blood urea nitrogen (S33)	No	No	No
Serum creatinine (S33)	No	No	No
Fasting glucose (S16)	No	No	Fasting insulin, HOMA-B, HOMA-IR, HbA1c, 2h glucose test, 2h insulin test, type 2 diabetes, DBP, SBP, hypertension, LDL, HDL, total cholesterol, triglycerides
Fasting insulin (S16)	No	No	Fasting insulin, HOMA-B, HOMA-IR, HbA1c, 2h glucose test, 2h insulin test, type 2 diabetes, DBP, SBP, hypertension, LDL, HDL, total cholesterol, triglycerides
HOMA-B (S16)	No	No	Fasting insulin, HOMA-B, HOMA-IR, HbA1c, 2h glucose test, 2h insulin test, type 2 diabetes, DBP, SBP, hypertension, LDL, HDL, total cholesterol, triglycerides
HOMA-IR (S16)	No	No	Fasting insulin, HOMA-B, HOMA-IR, HbA1c, 2h glucose test, 2h insulin test, type 2 diabetes, DBP, SBP, hypertension, LDL, HDL, total cholesterol, triglycerides

			2 diabetes, DBP, SBP, hypertension, LDL, HDL, total cholesterol, triglycerides
Major mood disorders (S44)	No	No	No
2h glucose challenge (S63)	No	No	Insulin secretion indices, T2D
PR interval (S57)	No	No	Atrial fibrillation
Hemoglobin (S24)	No	No	SBP, DBP, HTN
Hematocrit (S24)	No	No	SBP, DBP, HTN
Mean corpuscular volume (S24)	No	No	SBP, DBP, HTN
Mean corpuscular hemoglobin (S24)	No	No	SBP, DBP, HTN
Mean corpuscular hemoglobin concertation (S24)	No	No	SBP, DBP, HTN
Red blood cell count (S24)	No	No	SBP, DBP, HTN
Atrial fibrillation (S4)	No	No	No
Left ventricular mass (S80)	No	No	No
Left ventricle internal diastolic dimensions (S80)	No	No	No
Left ventricle wall thickness (S80)	No	No	No
Left ventricle systolic dysfunction (S80)	No	No	No
Adiposity- waist circumference (S43)	No	WHR	BMI, weight, height, bioimpedance data, DXA, hyperlipidemia, type 2 diabetes
Stroke (S29)	Yes	Stroke subtypes	No
Fibrinogen (S15)	No	No	No
QT interval (S56)	No	No	No

BMD, bone mineral density; BMI, body mass index; CAD, cIMT, carotid intima media thickness; coronary artery disease; CHD, coronary heart disease; DBP, diastolic blood pressure; FEV1, forced expiratory volume in 1 second; FN, femoral neck; FVC, forced vital capacity; GFR, glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, LDL, high density lipoprotein cholesterol; HOMA-B, homeostatic

model assessment beta cell function; HOMA-IR, homeostatic model assessment insulin resistance; HTN, hypertension; LDL, low density lipoprotein cholesterol; Lp-PLA2, lipoprotein-associated phospholipase A2; LS, lumbar spine; MCV, mean corpuscular volume; MetS, metabolic syndrome; MI, myocardial infraction; PTH, parathormone; SBP, systolic blood pressure; TGs, triglycerides; WC, waist circumference; WHR, waist to hip ratio

### Eligible reports of GWA meta-analyses:

- S1. Amin N, Byrne E, Johnson J, Chenevix-Trench G, Walter S, et al. 2012. Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM. *Mol Psychiatry* 17: 1116-29
- S2. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, et al. 2011. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. *Nat Genet* 43: 246-52
- S3. Arking DE, Juntila MJ, Goyette P, Huertas-Vazquez A, Eijgelsheim M, et al. 2011. Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome-wide association in European ancestry individuals. *PLoS Genet* 7: e1002158
- S4. Benjamin EJ, Rice KM, Arking DE, Pfeufer A, van Noord C, et al. 2009. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. *Nat Genet* 41: 879-81
- S5. Bis JC, Kavousi M, Franceschini N, Isaacs A, Abecasis GR, et al. 2011. Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. *Nat Genet* 43: 940-7
- S6. Boger CA, Chen MH, Tin A, Olden M, Kottgen A, et al. 2011. CUBN is a gene locus for albuminuria. *J Am Soc Nephrol* 22: 555-70
- S7. Boraska V, Day-Williams A, Franklin CS, Elliott KS, Panoutsopoulou K, et al. 2012. Genome-wide association study to identify common variants associated with brachial circumference: a meta-analysis of 14 cohorts. *PLoS One* 7: e31369



- S8. Bradfield JP, Qu HQ, Wang K, Zhang H, Sleiman PM, et al. 2011. A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci. *PLoS Genet* 7: e1002293
- S9. Bradfield JP, Taal HR, Timpson NJ, Scherag A, Lecoeur C, et al. 2012. A genome-wide association meta-analysis identifies new childhood obesity loci. *Nat Genet* 44: 526-31
- S10. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, et al. 2011. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. *Nat Genet* 43: 1131-8
- S11. Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, et al. 2011. Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. *PLoS Genet* 7: e1002033
- S12. Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, et al. 2012. Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. *PLoS Genet* 8: e1002607
- S13. de Moor MH, Costa PT, Terracciano A, Krueger RF, de Geus EJ, et al. 2012. Meta-analysis of genome-wide association studies for personality. *Mol Psychiatry* 17: 337-49
- S14. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, et al. 2011. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. *Circulation* 123: 731-8

- S15. Dehghan A, Yang Q, Peters A, Basu S, Bis JC, et al. 2009. Association of novel genetic Loci with circulating fibrinogen levels: a genome-wide association study in 6 population-based cohorts. *Circ Cardiovasc Genet* 2: 125-33
- S16. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. 2010. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat Genet* 42: 105-16
- S17. Eijgelsheim M, Newton-Cheh C, Sotoodehnia N, de Bakker PI, Muller M, et al. 2010. Genome-wide association analysis identifies multiple loci related to resting heart rate. *Hum Mol Genet* 19: 3885-94
- S18. Elks CE, Perry JR, Sulem P, Chasman DI, Franceschini N, et al. 2010. Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. *Nat Genet* 42: 1077-85
- S19. Estrada K, Styrkarsdottir U, Evangelou E, Hsu YH, Duncan EL, et al. 2012. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nat Genet* 44: 491-501
- S20. Evangelou E, Valdes AM, Kerkhof HJ, Styrkarsdottir U, Zhu Y, et al. 2011. Meta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteoarthritis on chromosome 7q22. *Ann Rheum Dis* 70: 349-55
- S21. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, et al. 2011. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nat Genet* 43: 761-7

- S22. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, et al. 2010. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet* 42: 1118-25
- S23. Freathy RM, Mook-Kanamori DO, Sovio U, Prokopenko I, Timpson NJ, et al. 2010. Variants in ADCY5 and near CCNL1 are associated with fetal growth and birth weight. *Nat Genet* 42: 430-5
- S24. Ganesh SK, Zakai NA, van Rooij FJ, Soranzo N, Smith AV, et al. 2009. Multiple loci influence erythrocyte phenotypes in the CHARGE Consortium. *Nat Genet* 41: 1191-8
- S25. Gieger C, Radhakrishnan A, Cvejic A, Tang W, Porcu E, et al. 2011. New gene functions in megakaryopoiesis and platelet formation. *Nature* 480: 201-8
- S26. Grallert H, Dupuis J, Bis JC, Dehghan A, Barbalic M, et al. 2012. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. *Eur Heart J* 33: 238-51
- S27. Heid IM, Jackson AU, Randall JC, Winkler TW, Qi L, et al. 2010. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. *Nat Genet* 42: 949-60
- S28. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, et al. 2011. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet* 43: 429-35

- S29. Ikram MA, Seshadri S, Bis JC, Fornage M, DeStefano AL, et al. 2009. Genomewide association studies of stroke. *N Engl J Med* 360: 1718-28
- S30. Ikram MK, Sim X, Jensen RA, Cotch MF, Hewitt AW, et al. 2010. Four novel Loci (19q13, 6q24, 12q24, and 5q14) influence the microcirculation in vivo. *PLoS Genet* 6: e1001184
- S31. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, et al. 2011. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* 478: 103-9
- S32. International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG, Sharma M, et al. 2011. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet* 377: 641-9
- S33. Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, et al. 2010. Genome-wide association study of hematological and biochemical traits in a Japanese population. *Nat Genet* 42: 210-5
- S34. Kaplan RC, Petersen AK, Chen MH, Teumer A, Glazer NL, et al. 2011. A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. *Hum Mol Genet* 20: 1241-51
- S35. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, et al. 2011. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. *Nat Genet* 43: 531-8

- S36. Kestenbaum B, Glazer NL, Kottgen A, Felix JF, Hwang SJ, et al. 2010. Common genetic variants associate with serum phosphorus concentration. *J Am Soc Nephrol* 21: 1223-32
- S37. Kiemeny LA, Sulem P, Besenbacher S, Vermeulen SH, Sigurdsson A, et al. 2010. A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. *Nat Genet* 42: 415-9
- S38. Kilpelainen TO, Zillikens MC, Stancakova A, Finucane FM, Ried JS, et al. 2011. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. *Nat Genet* 43: 753-60
- S39. Kooner JS, Saleheen D, Sim X, Sehmi J, Zhang W, et al. 2011. Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. *Nat Genet* 43: 984-9
- S40. Kristiansson K, Perola M, Tikkanen E, Kettunen J, Surakka I, et al. 2012. Genome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits. *Circ Cardiovasc Genet* 5: 242-9
- S41. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN, et al. 2010. Hundreds of variants clustered in genomic loci and biological pathways affect human height. *Nature* 467: 832-8
- S42. Ligthart L, de Vries B, Smith AV, Ikram MA, Amin N, et al. 2011. Meta-analysis of genome-wide association for migraine in six population-based European cohorts. *Eur J Hum Genet* 19: 901-7

- S43. Lindgren CM, Heid IM, Randall JC, Lamina C, Steinthorsdottir V, et al. 2009. Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution. *PLoS Genet* 5: e1000508
- S44. McMahon FJ, Akula N, Schulze TG, Muglia P, Tozzi F, et al. 2010. Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1. *Nat Genet* 42: 128-31
- S45. Meyer TE, Verwoert GC, Hwang SJ, Glazer NL, Smith AV, et al. 2010. Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels. *PLoS Genet* 6
- S46. Mitchell GF, Verwoert GC, Tarasov KV, Isaacs A, Smith AV, et al. 2012. Common genetic variation in the 3'-BCL11B gene desert is associated with carotid-femoral pulse wave velocity and excess cardiovascular disease risk: the AortaGen Consortium. *Circ Cardiovasc Genet* 5: 81-90
- S47. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, et al. 2010. A large-scale, consortium-based genomewide association study of asthma. *N Engl J Med* 363: 1211-21
- S48. Murabito JM, White CC, Kavousi M, Sun YV, Feitosa MF, et al. 2012. Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. *Circ Cardiovasc Genet* 5: 100-12
- S49. N'Diaye A, Chen GK, Palmer CD, Ge B, Tayo B, et al. 2011. Identification, replication, and fine-mapping of Loci associated with adult height in individuals of african ancestry. *PLoS Genet* 7: e1002298

- S50. O'Seaghdha CM, Yang Q, Glazer NL, Leak TS, Dehghan A, et al. 2010. Common variants in the calcium-sensing receptor gene are associated with total serum calcium levels. *Hum Mol Genet* 19: 4296-303
- S51. Okada Y, Kamatani Y, Takahashi A, Matsuda K, Hosono N, et al. 2010. A genome-wide association study in 19 633 Japanese subjects identified LHX3-QSOX2 and IGF1 as adult height loci. *Hum Mol Genet* 19: 2303-12
- S52. Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, et al. 2012. Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. *Nat Genet* 44: 511-6
- S53. Paternoster L, Standl M, Chen CM, Ramasamy A, Bonnelykke K, et al. 2012. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. *Nat Genet* 44: 187-92
- S54. Patsopoulos NA, Bayer Pharma MSGWG, Steering Committees of Studies Evaluating I-b, a CCRA, Consortium AN, et al. 2011. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. *Ann Neurol* 70: 897-912
- S55. Pattaro C, Kottgen A, Teumer A, Garnaas M, Boger CA, et al. 2012. Genome-wide association and functional follow-up reveals new loci for kidney function. *PLoS Genet* 8: e1002584
- S56. Pfeufer A, Sanna S, Arking DE, Muller M, Gateva V, et al. 2009. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. *Nat Genet* 41: 407-14

- S57. Pfeufer A, van Noord C, Marcianti KD, Arking DE, Larson MG, et al. 2010. Genome-wide association study of PR interval. *Nat Genet* 42: 153-9
- S58. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, et al. 2011. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. *Nat Genet* 43: 60-5
- S59. Qayyum R, Snively BM, Ziv E, Nalls MA, Liu Y, et al. 2012. A meta-analysis and genome-wide association study of platelet count and mean platelet volume in african americans. *PLoS Genet* 8: e1002491
- S60. Ramasamy A, Curjuric I, Coin LJ, Kumar A, McArdle WL, et al. 2011. A genome-wide meta-analysis of genetic variants associated with allergic rhinitis and grass sensitization and their interaction with birth order. *J Allergy Clin Immunol* 128: 996-1005
- S61. Reiner AP, Lettre G, Nalls MA, Ganesh SK, Mathias R, et al. 2011. Genome-wide association study of white blood cell count in 16,388 African Americans: the continental origins and genetic epidemiology network (COGENT). *PLoS Genet* 7: e1002108
- S62. Sanson M, Hosking FJ, Shete S, Zelenika D, Dobbins SE, et al. 2011. Chromosome 7p11.2 (EGFR) variation influences glioma risk. *Hum Mol Genet* 20: 2897-904
- S63. Saxena R, Hivert MF, Langenberg C, Tanaka T, Pankow JS, et al. 2010. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. *Nat Genet* 42: 142-8



- S64. Schizophrenia Psychiatric Genome-Wide Association Study Consortium. 2011. Genome-wide association study identifies five new schizophrenia loci. *Nat Genet* 43: 969-76
- S65. Schumann G, Coin LJ, Lourdasamy A, Charoen P, Berger KH, et al. 2011. Genome-wide association and genetic functional studies identify autism susceptibility candidate 2 gene (AUTS2) in the regulation of alcohol consumption. *Proc Natl Acad Sci U S A* 108: 7119-24
- S66. Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, et al. 2011. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nat Genet* 43: 333-8
- S67. Smith NL, Chen MH, Dehghan A, Strachan DP, Basu S, et al. 2010. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium. *Circulation* 121: 1382-92
- S68. Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, et al. 2010. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. *Circ Cardiovasc Genet* 3: 256-66
- S69. Smith NL, Huffman JE, Strachan DP, Huang J, Dehghan A, et al. 2011. Genetic predictors of fibrin D-dimer levels in healthy adults. *Circulation* 123: 1864-72

- S70. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, et al. 2011. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. *Nat Genet* 43: 1082-90
- S71. Soranzo N, Sanna S, Wheeler E, Gieger C, Radke D, et al. 2010. Common variants at 10 genomic loci influence hemoglobin A(1)(C) levels via glyceemic and nonglyceemic pathways. *Diabetes* 59: 3229-39
- S72. Sotoodehnia N, Isaacs A, de Bakker PI, Dorr M, Newton-Cheh C, et al. 2010. Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. *Nat Genet* 42: 1068-76
- S73. Speliotes EK, Willer CJ, Berndt SI, Monda KL, Thorleifsson G, et al. 2010. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat Genet* 42: 937-48
- S74. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, et al. 2010. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat Genet* 42: 508-14
- S75. Stolk L, Perry JR, Chasman DI, He C, Mangino M, et al. 2012. Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. *Nat Genet* 44: 260-8
- S76. Strawbridge RJ, Dupuis J, Prokopenko I, Barker A, Ahlqvist E, et al. 2011. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. *Diabetes* 60: 2624-34

- S77. Taal HR, St Pourcain B, Thiering E, Das S, Mook-Kanamori DO, et al. 2012. Common variants at 12q15 and 12q24 are associated with infant head circumference. *Nat Genet* 44: 532-8
- S78. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al. 2010. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* 466: 707-13
- S79. Tobacco Genetics Consortium. 2010. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. *Nat Genet* 42: 441-7
- S80. Vasani RS, Glazer NL, Felix JF, Lieb W, Wild PS, et al. 2009. Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. *JAMA* 302: 168-78
- S81. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al. 2010. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet* 42: 579-89
- S82. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, et al. 2011. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. *Nat Genet* 43: 1005-11
- S83. Walter S, Atzmon G, Demerath EW, Garcia ME, Kaplan RC, et al. 2011. A genome-wide association study of aging. *Neurobiol Aging* 32: 2109 e15-28

- S84. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, et al. 2010. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. *Lancet* 376: 180-8
- S85. Wen W, Cho YS, Zheng W, Dorajoo R, Kato N, et al. 2012. Meta-analysis identifies common variants associated with body mass index in east Asians. *Nat Genet* 44: 307-11
- S86. Yang Q, Kottgen A, Dehghan A, Smith AV, Glazer NL, et al. 2010. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. *Circ Cardiovasc Genet* 3: 523-30
- S87. Yasuno K, Bilguvar K, Bijlenga P, Low SK, Kirschke B, et al. 2010. Genome-wide association study of intracranial aneurysm identifies three new risk loci. *Nat Genet* 42: 420-5
- S88. Zhai G, Teumer A, Stolk L, Perry JR, Vandenput L, et al. 2011. Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms. *PLoS Genet* 7: e1002025